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Abstract	  31	  
	  32	   Cellular	  and	  molecular	  processes	  that	  mediate	  individual	  variability	  in	  impulsivity,	  a	  33	  
key	  behavioural	  component	  of	  many	  neuropsychiatric	  disorders,	  are	  poorly	  understood.	  34	  
Zebrafish	  heterozygous	  for	  a	  nonsense	  mutation	  in	  Ache	  (achesb55/+)	  showed	  lower	  35	  
levels	  of	  impulsivity	  in	  a	  5-­‐choice	  serial	  reaction	  time	  task	  (5-­‐CSRTT)	  than	  wild	  type	  and	  36	  
ache+/+.	  Assessment	  of	  expression	  of	  cholinergic	  (nAChR),	  serotonergic	  (5-­‐HT)	  and	  37	  
dopamine	  (DR)	  receptor	  mRNA	  in	  both	  adult	  and	  larval	  (9dpf)	  achesb55/+	  revealed	  38	  
significant	  downregulation	  of	  Chrna2,	  Chrna5	  and	  Drd2	  mRNA	  in	  achesb55/+	  larvae,	  but	  39	  
no	  differences	  in	  adults.	  	  Acute	  exposure	  to	  cholinergic	  agonist/antagonists	  had	  no	  40	  
effect	  on	  impulsivity,	  supporting	  the	  hypothesis	  that	  behavioural	  effects	  observed	  in	  41	  
adults	  were	  due	  to	  lasting	  impact	  of	  developmental	  alterations	  in	  cholinergic	  and	  42	  
dopaminergic	  signalling.	  This	  shows	  the	  cross-­‐species	  role	  of	  cholinergic	  signalling	  43	  
during	  brain	  development	  in	  impulsivity,	  and	  suggests	  zebrafish	  may	  be	  a	  useful	  model	  44	  
for	  the	  role	  of	  cholinergic	  pathways	  as	  a	  target	  for	  therapeutic	  advances	  in	  addiction	  45	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Introduction	  47	  
The	  identification	  of	  endophenotypes,	  as	  quantifiable,	  core	  components	  of	  complex	  48	  
behavioural	  traits	  and	  disease	  phenotypes	  makes	  genetic	  analysis	  of	  the	  pathogenesis	  of	  49	  
neuropsychiatric	  disease	  more	  tractable	  in	  both	  humans	  and	  model	  organisms	  50	  
(Burmeister	  et	  al.,	  2008b).	  	  One	  such	  potential	  endophenotype	  is	  impulsivity	  (Urcelay	  51	  
and	  Dalley,	  2012).	  Impulsivity	  not	  only	  is	  the	  hallmark	  symptom	  of	  a	  number	  of	  52	  
neuropsychiatric	  disorders	  (ADHD,	  addiction)	  but,	  in	  the	  case	  of	  addiction,	  has	  been	  53	  
shown	  to	  predict	  patterns	  of	  relapse	  and	  compulsive	  drug	  seeking	  in	  rats	  (Belin	  et	  al.,	  54	  
2008).	  	  55	  
Despite	  the	  well-­‐established	  role	  in	  a	  number	  of	  neuropsychiatric	  disorders,	  the	  56	  
cellular	  and	  molecular	  mechanisms	  that	  underlie	  impulsivity	  are	  not	  well	  understood.	  57	  
The	  cholinergic	  system,	  in	  particular	  cholinergic	  projections	  from	  the	  PFC,	  has	  long	  58	  
been	  implicated	  in	  sustained	  attention	  (Sarter	  et	  al.,	  2001).	  For	  example,	  IgG-­‐saporin	  59	  
lesions	  of	  cholinergic	  neurons	  in	  the	  basal	  forebrain	  reduce	  sustained	  attention	  60	  
(McGaughy	  and	  Sarter,	  1998),	  while	  systemic	  administration	  of	  the	  nAChR	  agonist	  61	  
nicotine	  improves	  performance	  accuracy	  and	  reduces	  omissions	  on	  the	  5-­‐CSRTT	  62	  
(Blondel	  et	  al.,	  2000;Hahn	  and	  Stolerman,	  2002;Young	  et	  al.,	  2004).	  In	  addition,	  63	  
infusions	  of	  scopolamine	  (mAchR	  antagonist)	  into	  the	  medial	  pre-­‐frontal	  cortex	  (mPFC),	  64	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al.,	  1998).	  The	  effects	  of	  chronic	  elevation	  of	  ACh,	  however,	  are	  less	  clear,	  although	  66	  
Grottick	  and	  Higgins	  (2000)	  found	  that	  improved	  performance	  accuracy	  is	  apparent	  67	  
with	  chronic	  nicotine	  exposure.	  The	  effects	  of	  genetic	  alteration	  of	  ACh	  activity	  have	  not	  68	  
previously	  been	  tested,	  particularly	  with	  respect	  to	  premature	  responding	  on	  the	  5-­‐69	  
CSRTT.	  70	  
Notwithstanding	  their	  small	  size,	  low	  housing	  costs	  and	  prolific	  breeding,	  there	  71	  
now	  exists	  a	  number	  of	  genetic	  tools	  for	  zebrafish	  research,	  including	  ENU	  mutagenized	  72	  
lines,	  extensive	  sperm	  libraries	  and	  a	  number	  of	  GFP/RFP	  lines.	  Despite	  anatomical	  73	  
differences	  between	  the	  fish	  and	  their	  mammalian	  counterparts,	  key	  neurochemical	  74	  
pathways	  are	  well	  conserved	  between	  the	  species	  (Guo,	  2004);	  for	  example,	  the	  75	  
ascending	  and	  descending	  midbrain	  catecholeminergic	  pathways	  (Guo	  et	  al.,	  1999).	  76	  
Here,	  we	  tested	  the	  performance	  of	  in	  Ache	  deficient	  (achesb55/+)	  zebrafish,	  for	  77	  
performance	  characteristics	  on	  the	  5-­‐CSRTT,	  a	  task	  designed	  to	  test	  aspects	  of	  impulse	  78	  
control	  through	  examination	  of	  anticipatory	  responding.	  achesb55	  contain	  a	  point	  79	  
mutation	  close	  to	  the	  catalytic	  site	  of	  the	  enzyme	  resulting	  in	  a	  replacement	  of	  Ser226	  80	  
by	  an	  Asn.	  Ser226	  is	  conserved	  in	  all	  ache	  gene	  family	  members,	  and	  is	  important	  for	  81	  
catalytic	  activity	  (Behra	  et	  al.,	  2002).	  Chronic	  alterations	  in	  cholinergic	  signalling	  with	  82	  
the	  acetylcholinesterase	  (AChE)	  inhibitor	  chlorpyrifos	  has	  previously	  been	  83	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for	  inquiry	  into	  the	  molecular	  mechanisms	  underlying	  impulse	  control	  (Middlemore-­‐85	  
Risher	  et	  al.,	  2010;Cardona	  et	  al.,	  2011;Oca	  et	  al.,	  2012).	  	  Zebrafish	  have	  previously	  been	  86	  
shown	  to	  respond	  well	  on	  the	  5-­‐CSRTT	  (Parker	  et	  al.,	  2012a;Parker	  et	  al.,	  2013a;Parker	  87	  
et	  al.,	  2014)	  88	   	  89	   	  90	  
Materials	  and	  Methods	  91	  
Ethics	  statement	  92	  
All	  experimental	  procedures,	  including	  drug	  dosing	  and	  behavioural	  testing,	  were	  93	  
carried	  out	  under	  the	  Animals	  (Scientific	  procedures)	  Act	  (1984).	  The	  procedures	  94	  
carried	  out	  conformed	  both	  to	  local	  ethical	  guidelines	  and	  to	  the	  terms	  of	  a	  project	  95	  
licence	  from	  the	  UK	  Home	  Office.	  In	  addition,	  all	  experiments	  were	  approved	  by	  the	  96	  
Queen	  Mary	  Animals	  Welfare	  and	  Ethical	  Review	  Board.	  97	  
	  98	  
Subjects	  99	  
Twenty-­‐nine	  (n=10	  achesb55/+(Ninkovic	  et	  al.,	  2006),	  n	  =	  19	  Tubingen	  wild-­‐type	  [w/t])	  100	  
adult	  zebrafish	  (age	  =	  6	  months;	  mixed	  sex)	  were	  selected	  for	  the	  first	  part	  of	  the	  study	  101	  
(5-­‐sec	  fixed	  interval	  PSI),	  and	  12	  adult	  zebrafish	  (age	  =	  5	  months;	  mixed	  sex;	  n	  =	  5	  102	  
achesb55/+;	  n	  =	  7	  ache+/+)	  were	  selected	  for	  the	  second	  part	  (Variable	  PSI).	  All	  were	  103	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aquarium	  facility	  at	  Queen	  Mary	  University	  of	  London	  according	  to	  standard	  protocols	  105	  
(Westerfield,	  1993).	  	  During	  the	  entire	  experimental	  period,	  fish	  were	  fed	  106	  
artemia/bloodworm	  mix	  during	  testing	  trials,	  and	  this	  was	  supplemented	  with	  flake	  107	  
food/artemia	  in	  the	  evenings	  and	  at	  weekends.	  	  108	  
	  109	  
Apparatus	  110	  
[FIGURE	  1	  HERE]	  111	  
Figure	  1	  displays	  the	  5-­‐CSRTT	  tanks	  used	  in	  the	  study.	  	  The	  shell	  of	  the	  testing	  tanks	  112	  
was	  constructed	  from	  opaque	  acrylic,	  as	  were	  the	  central	  gates.	  The	  lights	  were	  LEDs	  113	  
(magazine	  light	  green,	  stimulus	  aperture	  lights	  yellow).	  The	  reinforcer	  used	  was	  114	  
artemia	  liquidised	  with	  bloodworm,	  suspended	  in	  aquarium-­‐treated	  water	  (R-­‐O	  water	  115	  
with	  added	  salts).	  The	  food	  was	  delivered	  via	  a	  plastic	  syringe	  fitted	  with	  a	  1mm	  116	  
diameter	  rubber	  catheter	  tube,	  which	  was	  driven	  by	  a	  linear	  stepper	  motor	  (Figure	  1).	  	  117	  
	  118	  
General	  Procedure	  119	  
The	  main	  procedure	  is	  an	  extension	  and	  modification	  of	  the	  commonly	  used	  rodent	  5-­‐120	  
CSRTT,	  and	  has	  been	  described	  in	  detail	  elsewhere	  (Parker	  et	  al.,	  2012a;Parker	  et	  al.,	  121	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Pre-­‐training	  	  	  	  	  124	  
Prior	  to	  commencing	  training,	  all	  subjects	  were	  habituated	  to	  the	  test	  room	  for	  one	  125	  
week	  to	  acclimate	  to	  the	  conditions.	  All	  pre-­‐training,	  training	  and	  testing	  was	  carried	  126	  
out	  Monday-­‐Friday	  (0800-­‐1800),	  with	  the	  exception	  of	  the	  final	  stage	  (Stage	  8,	  see	  127	  
Table	  1),	  which	  was	  also	  carried	  out	  Saturday	  and	  Sunday.	  Training	  was	  divided	  into	  128	  
eight	  distinct	  stages	  (see	  Table	  1).	  	  129	  
[TABLE	  1	  HERE]	  130	  
During	  stages	  1-­‐3	  (pre-­‐training)	  data	  were	  collected	  and	  examined	  to	  ensure	  131	  
that	  all	  animals	  were	  receiving	  food	  during	  training.	  Any	  that	  did	  not	  perform	  the	  task	  132	  
(e.g.,	  froze	  in	  the	  tank	  or	  did	  not	  approach	  the	  lights;	  n	  <	  2	  on	  any	  given	  session)	  had	  133	  
their	  food	  supplemented	  immediately	  after	  the	  session.	  During	  acclimation	  (Stage	  1),	  134	  
fish	  were	  placed	  individually	  into	  the	  test	  tanks	  for	  30-­‐mins.	  During	  this	  all	  lights	  were	  135	  
illuminated	  and	  the	  gate	  was	  open.	  Immediately	  after	  acclimation,	  the	  fish	  were	  trained	  136	  
to	  enter	  the	  food	  magazine	  (Stage	  2).	  During	  this	  stage,	  the	  gate	  remained	  closed	  at	  all	  137	  
times.	  	  The	  magazine	  light	  was	  illuminated	  for	  30-­‐sec	  intervals,	  during	  which	  entry	  to	  138	  
the	  magazine	  resulted	  in	  the	  light	  turning	  off,	  and	  a	  small	  delivery	  (~20μl)	  of	  139	  
artemia/bloodworm	  mix.	  In	  Stage	  3	  the	  fish	  were	  trained	  to	  approach	  the	  response	  140	  
apertures.	  Here,	  the	  gate	  opened	  to	  reveal	  all	  of	  the	  response	  apertures	  illuminated,	  and	  141	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magazine	  light.	  Subsequent	  entry	  to	  the	  food	  magazine	  was	  reinforced	  with	  143	  
artemia/bloodworm	  mix.	  During	  Stage	  3	  (response	  aperture	  orientation)	  only	  fish	  that	  144	  
completed	  20	  or	  more	  correct	  trials	  were	  taken	  forward	  to	  5-­‐CSRTT	  training.	  	  	  145	  
	  146	  
Five-­‐Choice	  Serial	  Reaction	  Time	  Task:	  Phase	  1	  	  	  147	  
After	  a	  2-­‐min	  habituation	  period,	  the	  magazine	  light	  was	  illuminated,	  and	  entry	  to	  the	  148	  
food	  magazine	  initiated	  the	  trial	  sequence	  after	  an	  inter-­‐trial	  interval	  (ITI)	  of	  20-­‐	  149	  
secs1.	  This	  ITI	  always	  followed	  food	  delivery,	  and	  allowed	  the	  fish	  time	  to	  consume	  the	  150	  
reinforcer	  ration.	  	  After	  20-­‐secs,	  the	  gate	  was	  raised,	  and	  one	  of	  the	  stimulus	  apertures	  151	  
was	  illuminated	  after	  a	  pre-­‐stimulus	  interval	  (PSI).	  Entry	  to	  the	  correct	  aperture	  during	  152	  
the	  stimulus	  illumination,	  or	  during	  a	  brief	  pause	  thereafter	  (limited	  hold;	  LH),	  were	  153	  
conditionally	  reinforced	  by	  illumination	  of	  the	  magazine	  light,	  and	  the	  trial	  ended	  when	  154	  
the	  fish	  collected	  the	  food.	  All	  training	  sessions	  lasted	  30-­‐mins.	  For	  the	  first	  four	  weeks	  155	  
(Stage	  4)	  the	  fish	  were	  trained	  with	  30-­‐sec	  stimulus	  duration,	  a	  PSI	  of	  1-­‐sec	  and	  a	  1-­‐sec	  156	  
limited	  hold	  period.	  At	  all	  times	  during	  training	  and	  testing,	  the	  magazine	  light	  157	  
remained	  illuminated	  for	  30-­‐secs	  following	  a	  correct	  response,	  after	  which	  magazine	  158	  
entry	  was	  not	  reinforced.	  During	  the	  second	  stage	  of	  5-­‐CSRTT	  training	  (Stage	  5)	  the	  159	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stimulus	  duration	  was	  reduced	  to	  10-­‐sec,	  the	  PSI	  was	  increased	  to	  5-­‐sec	  and	  limited	  160	  
hold	  remained	  at	  1-­‐sec.	  The	  criterion	  for	  moving	  from	  each	  stage	  to	  the	  next	  was	  that	  161	  
the	  fish	  had	  reached	  a	  steady-­‐state	  response,	  operationalized	  as	  completing	  >20	  trials	  162	  
per	  session	  over	  5-­‐consecutive	  sessions.	  Any	  fish	  not	  meeting	  this	  criterion	  were	  163	  
excluded	  from	  the	  subsequent	  stage.	  	  164	  
	  165	  
Long	  PSI	  stage	  	  	  	  	  166	  
There	  were	  three	  long	  PSI	  sessions,	  during	  which	  the	  PSI	  was	  increased	  to	  7-­‐sec.	  All	  167	  
other	  test	  parameters	  remained	  the	  same	  as	  during	  Stage	  5	  (stimulus	  duration	  =	  10-­‐sec,	  168	  
limited	  hold	  =	  1-­‐sec).	  The	  three	  long	  PSI	  sessions	  were	  interspersed	  by	  two	  baseline	  169	  
sessions	  (Stage	  5;	  PSI	  =	  5-­‐sec,	  stimulus	  duration	  =	  10-­‐sec,	  limited	  hold	  =	  1-­‐sec).	  During	  170	  
the	  long	  PSI	  sessions,	  the	  length	  of	  the	  session	  was	  increased	  to	  35	  min.	  The	  criterion	  171	  
for	  a	  fish	  progressing	  to	  the	  long	  PSI	  phase	  of	  the	  experiment	  was	  that	  they	  reached	  172	  
steady	  state	  responding,	  again,	  operationally	  defined	  as	  having	  completed	  five	  sessions	  173	  
of	  >20	  trials	  prior	  to	  testing.	  Any	  fish	  that	  did	  not	  meet	  this	  criterion	  were	  excluded	  174	  
from	  the	  testing	  phase.	  	  175	  
	  176	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For	  the	  second	  phase	  of	  the	  experiment,	  we	  trained	  a	  group	  of	  experimentally	  naïve	  fish	  178	  
(n	  =	  5	  achesb55/+;	  n	  =	  7	  ache+/+)	  in	  an	  identical	  manner	  to	  that	  described	  above	  for	  stages	  179	  
1-­‐4.	  For	  Stage	  5,	  we	  introduced	  5-­‐second	  variable	  interval	  (VI)	  PSI.	  All	  other	  timings	  180	  
were	  the	  same	  as	  in	  Phase	  1,	  Stage	  5	  (stimulus	  duration	  =	  10-­‐sec,	  limited	  hold	  =	  1-­‐sec).	  181	  
There	  was	  no	  Long-­‐PSI	  stage	  in	  Phase	  2.	  	  182	  
	  183	  
Acute	  exposure	  to	  AChE	  antagonist,	  and	  nAChR	  and	  mAChR	  agonists	  184	  
Trained	  fish	  (w/t	  from	  Phase	  1)	  were	  selected	  for	  the	  drug	  administration	  phase.	  The	  185	  
exposure	  schedule	  was	  organised	  according	  to	  a	  full	  crossover	  design,	  with	  each	  fish	  186	  
receiving	  each	  of	  the	  drugs	  over	  a	  1-­‐week	  period.	  Fish	  were	  initially	  re-­‐trained	  (2-­‐187	  
weeks)	  in	  the	  absence	  of	  drug	  to	  establish	  steady-­‐state	  baseline	  performance	  (>20	  188	  
reinforced	  trials/session,	  for	  5	  sessions).	  The	  5-­‐CSRTT	  was	  as	  before	  in	  Stage	  5	  (see	  189	  
above:	  stimulus-­‐duration	  =	  10-­‐sec,	  PSI	  =	  5-­‐sec,	  LH	  =	  1-­‐sec),	  except	  that	  in	  this	  phase	  we	  190	  
employed	  a	  variable	  interval	  (VI)	  5-­‐second	  PSI.	  During	  the	  first	  experiment,	  there	  was	  191	  
no	  difference	  between	  the	  strains	  during	  the	  long	  PSI	  trials,	  but	  there	  was	  a	  difference	  192	  
during	  the	  earlier	  stages	  of	  training.	  As	  such,	  we	  chose	  to	  increase	  the	  complexity	  of	  the	  193	  
task	  by	  using	  a	  VI-­‐PSI	  during	  the	  entire	  training	  period.	  Immediately	  prior	  to	  training,	  194	  
fish	  were	  immersed	  in	  a	  pre-­‐treatment	  tank	  (1L)	  either	  in	  the	  drug	  solution	  or	  in	  195	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pilocarpine	  [Sigma-­‐Aldrich,	  UK]:	  8.64μM;	  Donepezil	  [Sigma-­‐Aldrich,	  UK]:	  2.63μM)	  were	  197	  
dissolved	  in	  aquarium-­‐treated	  H2O.	  Doses	  of	  Donepezil,	  nicotine	  and	  pilocarpine	  were	  198	  
selected	  based	  on	  previous	  work	  on	  attention/impulsivity	  (Day	  et	  al.,	  2007;Brembs,	  199	  
2009;Cardona	  et	  al.,	  2011).	  The	  dose	  of	  Donepezil	  was	  also	  based	  on	  an	  initial	  200	  
assessment	  of	  brain	  levels	  of	  ACh	  and	  AChE	  following	  drug	  administration	  to	  determine	  201	  
a	  dose	  that	  best	  reflected	  the	  ACh	  and	  AChE	  levels	  in	  ache	  sb55/+	  (Ninkovic	  et	  al.,	  2006).	  	  202	  
Brain	  levels	  of	  AChE	  and	  ACh	  were	  assessed	  in	  w/t	  fish	  exposed	  to	  2.63μM	  203	  
Donepezil	  or	  aquarium-­‐treated	  H2O	  for	  20	  mins	  using	  a	  fluorescence-­‐based	  approach	  204	  
(George	  et	  al.,	  1961).	  Following	  exposure	  to	  drug	  fish	  were	  placed	  in	  a	  recovery	  tank	  for	  205	  
5-­‐mins,	  and	  then	  killed	  by	  immersion	  in	  ice	  water.	  Brains	  were	  immediately	  removed,	  206	  
weighed	  and	  homogenized	  in	  ice-­‐cold	  Tris-­‐HCl	  (pH	  8).	  Samples	  were	  then	  centrifuged	  207	  
(20-­‐min	  at	  13,000	  RPM)	  and	  AChE	  and	  ACh	  was	  assessed	  from	  the	  resulting	  208	  
supernatant	  using	  Amplex	  Red	  Acetylcholine/Acetylcholinesterase	  assay	  kit	  (Molecular	  209	  
Probes,	  Invitrogen	  Detection	  Technologies,	  Paisley,	  UK)	  according	  to	  manufacturer’s	  210	  
instructions.	  Briefly,	  AChE	  converts	  ACh	  into	  choline,	  which	  is	  then	  oxidized	  by	  choline	  211	  
oxidase	  to	  betaine	  and	  H2O2.	  Brain	  levels	  of	  AChE	  and	  ACh	  were	  measured	  using	  10-­‐212	  
acetyl-­‐3,	  7-­‐dihydroxyphenoxazine,	  a	  flourogenic	  probe	  for	  H2O2.	  All	  ACh	  and	  AChE	  213	  
samples	  were	  examined	  in	  duplicate	  against	  standards	  and	  fluorescence	  was	  measured	  214	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Following	  exposure	  to	  2.63μM	  Donepezil,	  the	  levels	  of	  ACh	  were	  found	  to	  be	  higher	  in	  216	  
the	  drug	  group	  (11.8nM/g	  vs.	  7.1nM/g;	  t	  (8)	  =	  2.81,	  P	  =	  0.02),	  which	  was	  directly	  217	  
comparable	  to	  levels	  seen	  in	  the	  achesb55/+	  thus	  validating	  the	  dose	  used	  (Ninkovic	  et	  al.,	  218	  
2006).	  219	  
The	  exposure	  schedule	  was	  as	  follows:	  Week	  1:	  drug	  A,	  Week	  2:	  recovery	  (no	  220	  
drug),	  Week	  3:	  drug	  B,	  Week	  4:	  recovery,	  Week	  5:	  drug	  C.	  As	  stated,	  each	  fish	  was	  tested	  221	  
in	  the	  presence	  of	  each	  of	  the	  three	  drugs,	  the	  order	  of	  which	  was	  counterbalanced	  222	  
across	  weeks.	  	  223	  
	  224	  
Gene	  expression	  changes	  in	  achesb55/+	  	  225	  
[TABLE	  2	  HERE]	  226	  
We	  collected	  embryos	  from	  4	  x	  achesb55/+	  in-­‐crosses.	  All	  homozygous	  individuals	  were	  227	  
removed	  at	  72hpf	  (easily	  identifiable	  by	  morphological	  features	  and	  lack	  of	  motor	  228	  
activity)	  leaving	  petri	  dishes	  with	  ~2/3	  heterozygous	  individuals.	  We	  also	  collected	  229	  
embryos	  from	  4	  x	  ache+/+	  in-­‐crosses	  for	  comparison.	  Reference	  genes	  used	  were	  β-­‐actin,	  230	  
ef1α	  and	  rpl13α	  based	  on	  previous	  findings	  findings	  (Tang	  et	  al.,	  2007).	  Target	  genes	  231	  
used	  are	  listed	  in	  Table	  2.	  All	  embryos	  were	  manually	  sorted	  to	  ensure	  all	  were	  at	  the	  232	  
same	  developmental	  stage	  over	  the	  first	  72hpf,	  and	  grown	  to	  9dpf	  in	  petri	  dishes	  233	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MS-­‐222,	  and	  placed	  in	  RNAlater	  until	  assay	  (4ºC).	  Eight	  batches	  of	  n	  =	  3	  embryos	  per	  235	  
strain	  (ache	  sb55/+	  and	  ache+/+)	  were	  lysed	  in	  200µl	  Lysis	  buffer	  with	  2µl	  Proteinase	  K	  for	  236	  
30-­‐45min	  (55ºC).	  mRNA	  was	  isolated	  using	  40µl	  Dynabeads®	  Oligo(dT)25	  according	  to	  237	  
manufacturer’s	  instructions.	  Ten	  adult	  (6	  months)	  brains	  (n	  =	  5	  achesb55/+;	  n	  =	  5	  ache+/+)	  238	  
were	  homogenized	  in	  400µl	  Lysis	  buffer	  with	  4µl	  Proteinase	  K	  for	  30-­‐min	  (55ºC).	  mRNA	  239	  
was	  isolated	  using	  80µl	  Dynabeads®	  Oligo(dT)25	  according	  to	  manufacturer’s	  240	  
instructions.	  All	  qPCR	  reactions	  were	  carried	  out	  in	  triplicate.	  1µl	  of	  cDNA	  and	  1.5µl	  241	  
each	  of	  forward	  and	  reverse	  primers	  (see	  Table	  2)	  were	  added	  to	  5µl	  SYBR®	  Green	  PCR	  242	  
Master	  mix	  and	  run	  in	  a	  384-­‐well	  plate	  format	  (Roche	  Diagnostics).	  Method	  reported	  in	  243	  
full	  elsewhere	  (Gemenetzidis	  et	  al.,	  2010)	  (Teh	  et	  al.,	  2013).	  244	  
	  245	  
Data	  analysis	  246	  
5-­‐CSRTT	  data	  were	  fitted	  to	  general	  linear	  models	  (fit	  by	  REML),	  with	  time	  (5-­‐CSRTT	  247	  
phases	  1-­‐5)	  and	  strain	  (either	  achesb55/+	  vs.	  ache+/+	  or	  achesb55/+	  vs.	  w/t)	  as	  fixed	  effects.	  248	  
In	  the	  drug	  administration	  phase,	  drug	  (4-­‐levels,	  nicotine,	  pilocarpine,	  Donepezil	  and	  249	  
control)	  was	  added	  as	  a	  fixed	  factor,	  with	  ID	  and	  day	  as	  random	  effects.	  In	  each	  case,	  the	  250	  
dependent	  measure	  was	  calculated	  from	  performance	  in	  the	  5-­‐CSRTT:	  251	  
• Correct;	  calculated	  as:	           !"##$!%(!"##$!%  !  !"#$%%&#')	  252	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• Premature;	  calculated	  as:	  	  	  	  	  	   !"#$%&'"#!"##$!%  !  !"#$%%&#'  !  !"#!!"#$!  !  ! !"#$%&! 	  254	   	  255	  
Post-­‐hoc	  Tukey	  tests	  were	  carried	  out	  to	  examine	  main	  effects	  and	  interactions	  of	  5-­‐256	  
CSRTT	  data.	  	  257	  
Finally,	  to	  test	  the	  difference	  between	  levels	  of	  mRNA	  expression	  in	  larvae	  and	  258	  
adult	  achesb55/+	  and	  ache+/+	  siblings,	  we	  carried	  out	  a	  series	  of	  Mann-­‐Whitney	  U	  tests,	  259	  
with	  strain	  (achesb55/+	  vs	  ache+/+)	  as	  the	  independent	  variable	  and	  target	  gene	  260	  
expression,	  relative	  to	  reference	  genes,	  as	  the	  dependent	  variables.	  For	  mRNA	  261	  
expression	  data,	  P	  values	  were	  estimated	  following	  Bonferroni	  correction	  for	  multiple	  262	  
comparison.	  Effect	  sizes	  for	  all	  differences	  in	  expression	  were	  also	  calculated	  using	  the	  263	  
Grissom	  and	  Kim	  (2012)	  method.	  Descriptive	  statistics	  are	  reported	  as	  mean	  ±	  SEM	  264	  
unless	  otherwise	  stated.	  A	  type-­‐1	  error	  rate	  of	  α	  =	  0.05	  was	  adopted	  for	  all	  statistical	  265	  
tests.	  All	  data	  were	  analysed	  using	  IBM	  SPSS	  Statistics	  v.21	  for	  Macintosh.	  266	  
	  267	  
Results	  268	  
[FIGURE	  2	  HERE]	  269	  
achesb55/+	  show	  higher	  levels	  of	  responding	  during	  pre-­‐training	  270	  
The	  ache	  sb55/+	  heterozygotes	  were	  selected	  by	  systematic	  in-­‐crosses,	  the	  mutation	  being	  271	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pairwise	  comparisons	  revealed	  that	  there	  was	  a	  significant	  increase	  after	  Day	  1	  (Ps	  ≤	  273	  
0.05),	  but	  no	  change	  thereafter	  (Ps	  >	  0.6).	  There	  was	  also	  a	  significant	  main	  effect	  for	  274	  
strain,	  F	  (1,85)	  =	  5.61,	  P	  <	  0.01,	  with	  the	  achesb55/+	  making	  significantly	  more	  response	  275	  
than	  the	  w/t	  (Figure	  2a).	  There	  was	  no	  day	  ×	  strain	  interaction	  (F	  <	  1).	  Of	  the	  original	  39	  276	  
fish,	  3	  of	  the	  achesb55/+	  (30%)	  and	  8	  of	  the	  19	  w/t	  (42%)	  failed	  to	  meet	  criteria	  (i.e.,	  <	  20	  277	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  279	  
achesb55/+	  show	  lower	  levels	  of	  premature	  responding	  in	  long	  fixed-­‐interval	  and	  280	  
variable-­‐interval	  PSIs	  281	  
The	  rates	  of	  correct	  responses,	  omissions	  and	  premature	  responding	  were	  comparable	  282	  
with	  our	  previously	  published	  work	  with	  zebrafish	  (Parker	  et	  al.,	  2012a;Parker	  et	  al.,	  283	  
2013a;Parker	  et	  al.,	  2014).	  There	  was	  a	  significant	  main	  effect	  of	  phase	  for	  correct	  284	  
responses,	  F	  (4,24)	  =	  23.61,	  P	  <	  0.01.	  Post-­‐hoc	  tests	  revealed	  that	  the	  proportion	  of	  285	  
correct	  responses	  increased	  after	  phase	  1	  (phase	  1	  <	  phases	  3,	  4	  and	  long-­‐PSI,	  Ps	  <	  0.01,	  286	  
but	  not	  phase	  2,	  P	  =	  0.06)	  and	  phase	  2	  (phase	  2	  <	  phases	  3,	  4	  and	  long-­‐PSI,	  Ps	  >	  0.01),	  287	  
but	  there	  was	  no	  difference	  between	  phases	  3,	  4	  and	  long-­‐PSI	  (Ps	  >	  0.14).	  There	  was	  no	  288	  
main	  effect	  of	  strain	  (achesb55/+	  =	  0.52	  ±	  0.02,	  w/t=	  0.52	  ±	  0.02),	  F	  <	  1,	  nor	  a	  significant	  289	  
phase	  ×	  strain	  interaction,	  F	  <	  1.	  290	  
	   The	  rates	  of	  premature	  responding	  were	  comparable	  with	  our	  previous	  studies	  291	  
(Parker	  et	  al.,	  2012a;Parker	  et	  al.,	  2013b;Parker	  et	  al.,	  2014).	  There	  was	  a	  significant	  292	  
effect	  of	  phase,	  F	  (4,	  20)	  =	  37.17,	  P	  <	  0.01.	  Post-­‐hoc	  test	  revealed	  that	  phase	  1	  <	  phases	  293	  
2,	  3,	  4	  and	  long-­‐PSI	  (Ps	  <	  0.01),	  phase	  2	  <	  phases	  3,	  4	  and	  long-­‐PSI	  (Ps	  <	  0.01),	  phase	  3	  =	  294	  
phase	  4	  (P	  =	  0.3),	  and	  subjects	  performed	  more	  premature	  responses	  in	  the	  long-­‐PSI	  295	  
phase	  than	  phases	  3	  and	  4	  (Ps	  <	  0.05).	  There	  was	  also	  a	  significant	  main	  effect	  of	  strain	  296	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of	  premature	  responses	  than	  the	  w/t.	  There	  was	  no	  significant	  phase	  ×	  strain	  298	  
interaction,	  F	  (4,20)	  =	  2.11,	  P	  =	  0.12.	  299	  
	   Rates	  of	  omissions	  were	  again	  comparable	  with	  our	  previous	  study	  (Parker	  et	  al.,	  300	  
2012a;Parker	  et	  al.,	  2013b;Parker	  et	  al.,	  2014).	  There	  were	  significant	  main	  effects	  of	  301	  
phase,	  F	  (4,27)	  =	  22.02,	  P	  <	  0.01.	  Post-­‐hoc	  tests	  revealed	  that	  phase	  1	  <	  phases	  2,	  3,	  4	  302	  
and	  long-­‐PSI	  (Ps	  <	  0.01),	  and	  phase	  2	  >	  phases	  3	  and	  4	  (Ps	  <	  0.04),	  but	  not	  long-­‐PSI	  (P	  =	  303	  
0.3).	  Phase	  3	  was	  not	  significantly	  different	  from	  phase	  4	  (P	  =	  0.14)	  but	  was	  significantly	  304	  
lower	  than	  long-­‐PSI	  (P	  <	  0.03).	  There	  was	  no	  significant	  effect	  of	  strain	  (achesb55/+	  =	  0.32	  305	  
±	  0.02,	  w/t	  =	  0.31	  ±	  0.01),	  F	  <	  1,	  nor	  was	  there	  a	  significant	  phase	  ×	  strain	  interaction,	  F	  306	  
(4,27)	  =	  1.85,	  P	  =	  0.14.	  307	  
	   There	  was	  a	  significant	  effect	  of	  phase	  on	  the	  latency	  to	  approach	  the	  stimulus	  308	  
for	  correct	  responses,	  F	  (4,23)	  =	  26.91,	  P	  <	  0.01,	  with	  subjects	  taking	  longer	  to	  approach	  309	  
the	  stimulus	  in	  Phase	  1	  (12.69	  ±	  0.77	  s)	  than	  in	  phases	  2	  (4.51	  ±	  0.27	  s),	  3	  (5.31	  ±	  0.21	  310	  
s),	  4	  (5.45	  ±	  0.19	  s)	  or	  the	  long	  PSI	  phase	  (6.0	  ±	  0.18	  s).	  There	  was	  no	  significant	  effect	  311	  
of	  strain,	  F	  <	  1,	  nor	  was	  there	  a	  phase	  ×	  strain	  interaction,	  F	  (4,23)	  =	  1.18,	  P	  =	  0.35.	  	  312	  
	   The	  number	  of	  trials	  completed	  in	  each	  session	  during	  5-­‐CSRTT	  training	  changed	  313	  
significantly	  according	  to	  phase,	  F	  (4,30)	  =	  7.96,	  P	  <	  0.01,	  characterised	  as	  fish	  314	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phase	  4	  (Figure	  6).	  There	  was	  no	  main	  effect	  of	  strain,	  F	  <	  1	  nor	  a	  phase	  ×	  strain	  316	  
interaction,	  F	  <	  1.	  317	  
	   Finally,	  we	  carried	  out	  a	  replication	  with	  achesb55/+	  heterozygotes	  and	  ache+/+	  318	  
wild-­‐type	  siblings.	  First,	  fish	  were	  trained	  for	  20	  sessions	  (1-­‐sec	  fixed	  interval	  PSI),	  and	  319	  
finally	  with	  six,	  5-­‐second	  variable-­‐interval	  (VI)	  PSI	  trials	  included.	  achesb55/+	  showed	  a	  320	  
significantly	  lower	  proportion	  of	  premature	  responses	  during	  the	  VI-­‐PSI	  trials,	  F	  (1,	  18)	  321	  
=	  10.48,	  P	  =	  0.03	  (Figure	  2c).	  There	  were	  no	  differences	  in	  correct	  responses	  (achesb55/+	  322	  
=	  0.66	  ±	  0.03;	  ache+/+	  =	  0.61	  ±	  0.02;	  P	  =	  0.13),	  nor	  omissions	  (achesb55/+	  =	  0.34	  ±	  0.05;	  323	  
ache+/+	  =	  0.24	  ±	  0.03;	  P	  =	  0.1).	  324	  
	  325	  
Acute	  manipulation	  of	  cholinergic	  activity	  increases	  performance	  accuracy	  but	  326	  
has	  no	  effect	  on	  anticipatory	  responding	  in	  adult	  wild-­‐type	  zebrafish	  327	  
	  328	  
Figure	  2d	  shows	  the	  results	  of	  drug	  administration	  on	  5-­‐CSRTT	  performance	  in	  wild-­‐329	  
type	  fish.	  There	  was	  a	  significant	  main	  effect	  of	  drug	  on	  correct	  responses,	  F	  (3,75)	  =	  330	  
4.01,	  P	  =	  0.01.	  Post-­‐hoc	  pairwise	  comparisons	  (α-­‐adjusted	  for	  multiple	  tests)	  revealed	  331	  
that	  there	  was	  a	  significant	  increase	  from	  control	  in	  correct	  responses	  during	  the	  332	  
nicotine	  (P	  =	  0.02)	  but	  not	  pilocarpine	  (P	  =	  0.19)	  or	  Donepezil	  (P	  =	  0.85).	  There	  were	  no	  333	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0.68)	  or	  pilocarpine	  and	  Donepezil	  (P	  =	  0.53).	  There	  were	  no	  differences	  between	  the	  335	  
drugs’	  effects	  in	  terms	  of	  premature	  response	  rates	  (control	  =	  0.126	  ±	  0.02;	  nicotine	  =	  336	  
0.104	  ±	  0.03;	  pilocarpine	  =	  0.103	  ±	  0.03;	  Donepezil	  =	  0.13	  ±	  0.03;	  F	  <	  1),	  nor	  in	  terms	  of	  337	  
omissions	  (control	  =	  0.08	  ±	  0.03;	  nicotine	  =	  0.1	  ±	  0.04;	  pilocarpine	  =	  0.1	  ±	  0.04;	  338	  
Donepezil	  =	  0.13	  ±	  0.04;	  F	  (3,	  79)	  =	  1.22,	  P	  =	  0.3).	  There	  were	  no	  differences	  in	  the	  total	  339	  
number	  of	  trials	  completed	  in	  each	  session	  (control	  =	  21.4	  ±	  0.52;	  nicotine	  =	  19.2	  ±	  0.94;	  340	  
pilocarpine	  =	  21.7	  ±	  0.94;	  Donepezil	  =	  21.4	  ±	  0.94;	  F	  (3,	  80)	  =	  1.77,	  P	  =	  0.16).	  Finally,	  341	  
there	  was	  no	  effect	  of	  drug	  on	  approach	  latency	  (control	  =	  8.6	  ±	  1.3;	  nicotine	  =	  8.8	  ±	  1.5;	  342	  
pilocarpine	  =	  9.1	  ±	  1.5;	  Donepezil	  =	  9.1	  ±	  1.5;	  F	  <	  1).	  343	  
	  344	  
achesb55/+	  have	  down	  regulation	  of	  chrna2,	  chrna5	  and	  drd2	  mRNA	  at	  9dpf,	  but	  no	  345	  
detectable	  differences	  in	  adult	  expression	  346	  
[TABLE	  3	  HERE]	  347	  
Finally,	  to	  help	  understand	  the	  mechanisms	  by	  which	  developmental	  reduction	  in	  AChE	  348	  
affected	  the	  observed	  reduction	  in	  anticipatory	  responding,	  we	  characterized	  the	  gene	  349	  
expression	  profile	  of	  achesb55/+	  focussing	  on	  neural	  circuits	  known	  to	  be	  involved	  in	  350	  
impulse	  control.	  Table	  3	  summarises	  the	  differences	  in	  mRNA	  expression	  for	  achesb55/+	  351	  
heterozygotes	  vs	  ache+/+	  wild-­‐type	  siblings.	  	  We	  found	  that	  in	  the	  achesb55/+	  352	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genes	  that	  code	  for	  the	  alpha-­‐2,	  alpha-­‐5	  receptor	  subunits	  (nAChRa2,	  nAChRa5),	  and	  the	  354	  
dopamine	  d2	  receptor	  subunit	  (DRD2),	  respectively.	  In	  the	  adults,	  there	  was	  no	  355	  
difference	  in	  expression	  of	  any	  of	  the	  genes	  we	  observed.	  356	  
	  357	  
Discussion	  358	  
The	  aim	  of	  this	  experiment	  was	  to	  test	  the	  hypothesis	  that	  developmental	  alterations	  in	  359	  
cholinergic	  signalling	  affect	  impulse	  control	  using	  a	  zebrafish	  model	  of	  the	  commonly	  360	  
used	  5-­‐CSRTT	  with	  a	  strain	  heterozygous	  for	  a	  missense	  mutation	  in	  Ache	  (achesb55/+).	  361	  
We	  found	  that	  achesb55/+	  showed	  a	  lower	  proportion	  of	  premature	  responding	  than	  362	  
achesb55/+	  siblings	  and	  w/t	  zebrafish.	  There	  were	  no	  significant	  differences	  in	  either	  the	  363	  
number	  of	  correct	  responses,	  latency	  to	  respond,	  number	  of	  trials	  or	  the	  number	  of	  364	  
omissions,	  although	  the	  achesb55/+	  appeared	  to	  learn	  faster,	  collecting	  more	  reinforcers	  365	  
during	  pre-­‐training.	  Acute	  reductions	  of	  AChE	  (donepezil)	  had	  no	  significant	  effects	  on	  366	  
premature	  responding,	  or	  other	  5-­‐CSRTT	  parameters,	  and	  acute	  administration	  of	  a	  367	  
nAChR	  agonist	  significantly	  increased	  performance	  accuracy,	  while	  having	  no	  effect	  on	  368	  
premature	  responding.	  Finally,	  achesb55/+	  have	  a	  down	  regulation	  of	  chrna2,	  chrna5,	  and	  369	  
drd2	  mRNA	  expression	  at	  9dpf,	  but	  no	  difference	  in	  expression	  in	  any	  of	  the	  genes	  we	  370	  
examined	  in	  adulthood.	  Previous	  studies	  have	  shown	  that	  high	  levels	  of	  AChE	  inhibition	  371	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(Middlemore-­‐Risher	  et	  al.,	  2010;Cardona	  et	  al.,	  2011;Oca	  et	  al.,	  2012))	  increase	  373	  
impulsivity	  in	  later	  life.	  Collectively,	  these	  data	  provide	  the	  first	  evidence	  that	  variation	  374	  
in	  AChE	  during	  development	  has	  a	  J-­‐shaped	  effect	  on	  impulse	  control,	  potentially	  375	  
through	  downstream	  effects	  on	  cholinergic	  and	  dopaminergic	  pathways.	  376	  
Lesion,	  neuropsychological	  and	  pharmacological	  studies	  have	  demonstrated	  that	  377	  
cortical	  cholinergic	  projections	  to	  mid-­‐brain	  regions	  are	  strongly	  implicated	  in	  378	  
sustained	  attention	  and	  in	  general	  top-­‐down	  cognitive	  control	  (Sarter	  et	  al.,	  2001).	  In	  379	  
particular,	  during	  5-­‐CSRTT	  performance	  rats	  display	  elevated	  ACh	  release	  from	  the	  380	  
medial	  pre-­‐frontal	  cortex	  (mPFC),	  and	  phasic	  increases	  in	  ACh	  release	  when	  a	  visual	  381	  
distracter	  was	  introduced	  to	  increase	  task	  complexity	  (Passetti	  et	  al.,	  2000).	  We	  did	  not	  382	  
see	  any	  differences	  in	  the	  number	  of	  correct	  responses	  in	  our	  version	  of	  the	  task,	  but	  383	  
more	  of	  the	  achesb55/+	  met	  criteria	  to	  move	  to	  the	  5-­‐CSRTT	  stage	  of	  training,	  and	  of	  those	  384	  
that	  met	  criteria,	  overall	  performance	  in	  terms	  of	  reinforcers	  gained	  was	  significantly	  385	  
greater	  than	  the	  w/t.	  This	  finding	  replicates	  assessment	  of	  this	  strain’s	  learning	  386	  
previously	  demonstrated	  in	  a	  T-­‐maze	  task	  (Ninkovic	  et	  al.,	  2006).	  During	  this	  initial	  387	  
training	  stage,	  despite	  the	  strain	  difference,	  there	  was	  no	  day	  ×	  strain	  interaction,	  388	  
suggesting	  that	  achesb55/+	  learnt	  at	  the	  same	  rate.	  It	  may	  be	  that	  the	  achesb55/+	  were	  389	  
more	  motivated	  to	  perform,	  or	  habituated	  faster	  than	  the	  w/t.	  This	  effect	  was	  transient,	  390	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evidence	  for	  the	  role	  of	  nAChR	  in	  task	  performance,	  with	  acute	  exposure	  to	  nicotine	  392	  
(nAChR	  agonist)	  increasing	  the	  proportion	  of	  correct	  responses	  in	  the	  task.	  This	  393	  
supports	  previous	  data	  from	  rodents	  (Blondel	  et	  al.,	  2000;Hahn	  and	  Stolerman,	  394	  
2002;Young	  et	  al.,	  2004).	  	  395	  
A	  potential	  mechanism	  for	  the	  observed	  differences	  in	  premature	  responding	  396	  
may	  relate	  to	  the	  role	  of	  nAChR	  during	  early	  brain	  development	  and	  patterning.	  nAChR	  397	  
subtypes,	  in	  particular	  α4,	  α5,	  α7,	  	  β2	  and	  β4,	  are	  found	  early	  in	  brain	  development,	  and	  398	  
have	  been	  suggested	  to	  play	  a	  role	  in	  modulating	  and	  mediating	  early	  patterning,	  399	  
dendritic	  outgrowth	  and	  synaptogenesis	  (Hellström-­‐Lindahl	  et	  al.,	  1998).It	  is	  possible	  400	  
therefore	  that	  reduction	  in	  AChE	  levels,	  as	  is	  characteristic	  of	  the	  achesb55/+	  401	  
heterozygotes,	  during	  early	  brain	  development	  alter	  the	  distribution	  of	  nAChRs	  thus	  402	  
causing	  differences	  in	  patterning	  and	  dendritic	  morphology.	  Indeed,	  in	  zebrafish,	  AChE	  403	  
enzymatic	  activity	  has	  been	  shown	  to	  be	  important	  for	  both	  axon	  outgrowth	  and	  404	  
synapse	  stability,	  albeit	  within	  the	  neuromuscular	  projections	  of	  the	  nervous	  system	  405	  
(Behra	  et	  al.,	  2002;Downes	  and	  Granato,	  2004).	  	  406	  
Chronic	  reductions	  of	  AChE	  in	  adult	  rats	  with	  donepezil	  increases	  expression	  of	  407	  
α4	  and	  α7	  nAChR	  (Kume	  et	  al.,	  2005),	  and	  ACh-­‐modulated	  reductions	  in	  impulsive	  408	  
action	  in	  the	  3-­‐CSRTT	  are	  mediated	  by	  α4	  nAChR	  (Tsutsui-­‐Kimura	  et	  al.,	  2010).	  409	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observe	  robust	  down	  regulation	  of	  chrna2	  and	  chrna5	  mRNA	  expression	  in	  the	  achesb55/+	  411	  
heterozygotes	  at	  9dpf,	  but	  no	  differences	  in	  adulthood.	  CHRNA2	  and	  CHRNA5	  variants	  412	  
have	  been	  shown	  to	  predict	  impulsive	  responding	  in	  response-­‐inhibition	  in	  humans	  413	  
(Rigbi	  et	  al.,	  2008),	  and	  transgenic	  mice	  overexpressing	  the	  Chrna3,	  Chrna5,	  Chrnb4	  414	  
gene	  cluster	  show	  a	  reduction	  in	  impulsivity	  (Viñals	  et	  al.,	  2012).	  However,	  the	  415	  
differences	  in	  behaviour	  observed	  in	  the	  achesb55/+	  heterozygotes	  demonstrate	  416	  
haploinsufficiency	  of	  the	  AChE	  gene,	  and	  thus	  has	  implications	  for	  the	  impact	  of	  AChE	  417	  
mutations	  within	  the	  human	  population.	  Although	  we	  are	  yet	  to	  understand	  the	  418	  
mechanism,	  this	  may	  inform	  our	  exploration	  of	  potential	  targets	  for	  therapeutics	  in	  the	  419	  
future.	  420	  
The	  functional	  properties	  of	  nAChRs	  on	  catecholaminergic	  (in	  particular,	  421	  
dopaminergic)	  axonal	  terminals	  alter	  during	  development,	  highlighting	  their	  role	  in	  the	  422	  
development	  of	  the	  dopamine	  system	  (Azam	  et	  al.,	  2007).	  	  It	  is	  clear	  that	  over-­‐activation	  423	  
of	  nAChR	  during	  early	  development,	  e.g.,	  from	  maternal	  smoking	  during	  pregnancy,	  can	  424	  
result	  in	  an	  increased	  risk	  for	  impulse	  control	  disorders	  (Button	  et	  al.,	  2007).	  In	  425	  
addition,	  as	  discussed	  above,	  excessive	  inhibition	  of	  AChE	  during	  development,	  426	  
resulting	  from	  exposure	  to	  the	  organophosphate	  insecticide	  chlorpyrifos,	  results	  in	  427	  
higher	  impulsivity	  (Middlemore-­‐Risher	  et	  al.,	  2010;Cardona	  et	  al.,	  2011;Oca	  et	  al.,	  428	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system	  disruption	  and	  impulsivity,	  it	  is	  not	  clear	  at	  this	  stage	  the	  mechanisms	  by	  which	  430	  
subtle	  alterations,	  such	  as	  are	  seen	  with	  achesb55/+,	  subsequently	  reduces	  impulsivity.	  It	  431	  
is	  possible	  that	  this	  reflects	  species-­‐specific	  differences	  in	  patterning	  during	  early	  brain	  432	  
ontogeny,	  although	  this	  seems	  unlikely	  based	  on	  documented	  similarities	  between	  fish	  433	  
and	  mammalian	  cholinergic	  system	  development	  (Xie	  et	  al.,	  2000;Behra	  et	  al.,	  2002).	  434	  
During	  development,	  AChE	  is	  transiently	  involved	  with	  aspects	  of	  neural	  435	  
patterning	  and	  hodological	  development.	  For	  example,	  during	  cortical	  synaptogenesis	  436	  
and	  development	  of	  thalamo-­‐cortical	  pathways,	  AChE	  activity	  is	  recorded	  in	  various	  437	  
brain	  regions	  (Button	  et	  al.,	  2007).	  The	  cholinergic	  system	  interacts	  with	  mid-­‐brain	  438	  
dopamine	  activity	  in	  a	  number	  of	  ways.	  First,	  the	  nucleus	  accumbens	  (NAc)	  is	  densely	  439	  
innervated	  by	  cholinergic	  projection	  neurons	  (Meredith	  et	  al.,	  1989;Woolf,	  1991).	  440	  
Second,	  cholinergic	  receptors	  (both	  muscarinic	  [mAChR]	  and	  nicotinic	  [nAChR])	  are	  441	  
found	  on	  ventral	  tegmental	  area	  (VTA)	  dopamine	  neurons,	  suggesting	  dopaminergic	  442	  
control	  of	  cholinergic	  activity	  (Clarke	  and	  Pert,	  1985).	  Third,	  mesolimbic	  cholinergic	  443	  
projection	  neurons	  are	  abundant	  with	  dopamine	  receptors,	  suggesting	  cholinergic	  444	  
mediation	  of	  dopamine	  activity	  (Gronier	  et	  al.,	  2000),	  creating	  a	  feedback	  loop.	  Rats	  445	  
characterised	  as	  high	  trait	  impulsivity	  based	  on	  baseline	  performance	  on	  the	  5-­‐CSRTT	  446	  
show	  a	  greater	  tendency	  for	  elevated	  cocaine	  self-­‐administration	  (Dalley	  et	  al.,	  2007),	  447	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compulsive	  cocaine	  seeking	  following	  punishment-­‐induced	  abstinence	  (Economidou	  et	  449	  
al.,	  2009).	  In	  addition,	  high	  impulsive	  rats	  show	  a	  reduction	  in	  DRD2/DRD3	  receptors	  in	  450	  
the	  ventral	  striatum,	  suggesting	  a	  potential	  biomarker	  for	  the	  addiction	  phenotype	  451	  
(Dalley	  et	  al.,	  2007).	  Interestingly,	  achesb55/+	  have	  previously	  been	  characterised	  as	  452	  
showing	  a	  decrease	  in	  conditioned	  place	  preference	  (CPP)	  for	  amphetamine	  (Ninkovic	  453	  
et	  al.,	  2006).	  It	  is	  well	  established,	  through	  the	  therapeutic	  efficacy	  of	  dopamine	  agonists	  454	  
such	  as	  methylphenidate	  in	  reducing	  impulsivity	  in	  ADHD	  patients	  (Barkley,	  1997),	  that	  455	  
impulsivity	  is,	  at	  least	  in	  part,	  related	  to	  a	  reduction	  in	  availability	  of	  dopamine	  (Li	  et	  al.,	  456	  
2006).	  As	  such,	  it	  seems	  possible	  that	  as	  genetic	  impairment	  of	  AChE	  in	  achesb55/+,	  which	  457	  
results	  in	  higher	  levels	  of	  circulating	  ACh	  and	  as	  such,	  desensitization	  of	  AChRs	  458	  
(Ninkovic	  et	  al.,	  2006),	  may	  act	  to	  stabilise	  dopamine	  activity	  (Zhou	  et	  al.,	  2001),	  thus	  459	  
decreasing	  impulsive	  responding.	  However,	  although	  we	  observed	  downregulation	  in	  460	  
drd2	  mRNA	  in	  9dpf	  achesb55/+	  embryos,	  there	  was	  no	  significant	  differences	  in	  the	  461	  
adults.	  As	  such,	  this	  requires	  further	  exploration	  in	  order	  to	  elucidate	  the	  mechanism.	  462	  
In	  rodents,	  low	  levels	  of	  premature	  responding	  in	  the	  5-­‐CSRTT	  are	  predictive	  of	  463	  
animals	  that	  show	  resistance	  to	  developing	  compulsive	  drug	  seeking	  (Belin	  et	  al.,	  2008)	  464	  
and	  relapse	  following	  abstinence	  (Economidou	  et	  al.,	  2009),	  and	  this	  has	  been	  465	  
interpreted	  as	  these	  animals	  showing	  low	  levels	  of	  trait	  impulsivity	  affecting	  top-­‐down	  466	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not	  well	  understood	  (Brown	  et	  al.,	  2006;Chang	  et	  al.,	  2012),	  but	  these	  findings	  suggest	  468	  
that	  zebrafish,	  an	  established	  genetic	  model	  system,	  offer	  a	  means	  for	  exploration	  of	  469	  
this.	  	  470	  
Gaining	  a	  better	  understanding	  of	  the	  aetiology	  of	  psychiatric	  disease	  is	  471	  
currently	  a	  priority	  area	  of	  research	  (Campbell,	  2010),	  and	  with	  current	  advances	  in	  472	  
neuroimaging	  and	  huge	  increases	  in	  genetic	  sequencing	  power	  this	  aim	  is	  beginning	  to	  473	  
be	  realised.	  For	  example,	  genome-­‐wide	  association	  studies	  (GWAS)	  are	  making	  progress	  474	  
in	  this	  regard	  (Sullivan,	  2010),	  but	  are	  limited	  by	  uncontrollable	  factors	  such	  as	  475	  
environmental	  influences	  and	  heterogeneity	  of	  diseases	  (Burmeister	  et	  al.,	  2008a).	  	  As	  476	  
such,	  animal	  models	  have	  proved	  useful	  in	  terms	  of	  identifying	  molecular	  mechanisms	  477	  
of	  many	  psychiatric	  diseases,	  as	  symptoms	  consistent	  with	  DSM-­‐IV	  (APA,	  2000)	  478	  
diagnoses	  of	  psychiatric	  disorder	  have	  been	  characterised	  in	  many	  models	  (Gould	  and	  479	  
Gottesman,	  2006).	  A	  better	  understanding	  of	  the	  molecular	  mechanisms	  will	  be	  helpful	  480	  
in	  tailoring	  treatment	  options	  for	  patients,	  but	  also	  for	  early	  identification	  of	  at-­‐risk	  481	  
individuals	  to	  allow	  preventative	  measures	  to	  be	  adopted	  in	  the	  early	  stages	  of	  the	  482	  
disorder	  (Uhl	  et	  al.,	  2008).	  Progress	  in	  identifying	  molecular	  mechanisms,	  however,	  has	  483	  
remained	  slow.	  This	  study	  shows	  more	  evidence	  that	  zebrafish	  may	  be	  very	  useful	  in	  484	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In	  conclusion,	  this	  study	  has	  found	  that	  alterations	  in	  Ache	  reduce	  premature	  486	  
responding	  in	  zebrafish	  on	  the	  5-­‐CSRTT.	  This	  effect	  appears	  to	  relate	  specifically	  to	  487	  
developmental	  effects	  of	  reduced	  AChE,	  as	  acute	  exposure	  to	  an	  AChE	  antagonist	  had	  no	  488	  
effect	  on	  premature	  responding	  in	  the	  task.	  Molecular	  analyses	  suggest	  that	  the	  route	  of	  489	  
action	  may	  be	  through	  cholinergic	  interactions	  with	  midbrain	  dopamine	  systems	  during	  490	  
development.	  This	  study	  opens	  the	  door	  for	  potential	  large-­‐scale	  forward	  genetic	  491	  
population	  screening	  of	  mutagenized	  lines	  of	  zebrafish	  to	  identify	  novel	  alleles	  for	  492	  
phenotypes	  such	  as	  impulsivity,	  which	  is	  crucial	  in	  the	  search	  for	  novel	  therapeutics	  and	  493	  
individualised	  medicine	  (Jain	  et	  al.,	  2011).	  	  494	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Figure/Table	  legends	  713	   	  714	  
Figure	  1.	  	  Testing	  unit	  and	  the	  constituent	  parts.	  A)	  The	  pneumatic	  gate	  mechanism.	  B)	  715	   The	  stimulus	  light	  area.	  The	  stimuli	  were	  5	  white	  LEDs.	  C)	  The	  food	  delivery	  area	  and	  716	   magazine.	  This	  comprised	  a	  green	  LED	  to	  act	  as	  a	  stimulus	  to	  signal	  food	  availability.	  D)	  717	   Food	  was	  delivered	  via	  activation	  of	  a	  linear	  stepper	  motor	  driving	  the	  plunger	  of	  a	  718	   1.5ml	  plastic	  syringe,	  E).	  The	  food	  (liquidized	  bloodworm	  and	  brine-­‐shrimp)	  was	  719	   delivered	  to	  the	  fish	  through	  1mm	  latex	  catheter	  tubing.	  Adapted	  from	  (Parker	  et	  al.,	  720	   2012b)	  721	   	  722	  
Figure	  2.	  Five-­‐choice	  serial	  reaction	  time	  task	  data.	  A)	  ache	  sb55/+	  receive	  more	  723	   reinforcers	  in	  the	  stimulus-­‐light	  training	  session	  that	  TU	  wild-­‐type	  fish;	  B)	  ache	  sb55/+	  724	   perform	  a	  lower	  proportion	  of	  anticipatory	  responses	  during	  5-­‐CSRTT	  training	  than	  TU	  725	   wild-­‐type;	  C)	  ache	  sb55/+	  perform	  a	  lower	  proportion	  of	  anticipatory	  responses	  in	  5-­‐726	   CSRTT	  thank	  ache	  +/+;	  D)	  1.54uM	  nicotine	  increases	  proportion	  of	  correct	  responses	  727	   during	  5-­‐CSRTT	  in	  TU	  wild-­‐type	  fish.	  Note:	  *	  P	  <	  0.05;	  **	  P	  <	  0.01	  728	   	  729	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Table	  1.	  Procedure	  for	  pre-­‐training	  and	  training	  during	  5-­‐CSRTT.	  731	   	  732	  
733	  
	   	  734	  
Stage Procedure Description Timecourse
Pretraining 1. Acclimation All apparatus lights on, barrier raised Day 1-5
2. Magazine
training





All stimulus lights illuminated. Barrier lifted, all stimulus lights illuminated. Entry 
to any hole reinforced with illumination of magazine light. Food delivered on entry 






Trial commences with barrier lifted, followed by 1-sec pause (ITI). Stimulus lights
illuminated in random order (30-sec), followed by 1-sec limited hold period 
(stimulus light off). Responses during the stimulus or the limited hold conditionally 
reinforced with illumination of magazine light. Food delivered on entry to 
magazine. Barrier down after correct response. Ten second pause following 
magazine entry (stimulus lights off, barrier down). Subsequent trial initiated 




As above (4), but stimulus light illuminated for 10-sec Days 36-45
6. 5-sec stimulus
light, 2-sec ITI
As above (4), but stimulus light illuminated for 5-sec, and ITI increased to 2-sec Day 46-55
7. 5-sec stimulus
light, 5-sec ITI 
(Baseline)
As above (6), but ITI increased to 5-sec. Day 56-60
Testing
8. Long ITI training
Day 1 - Long ITI (as above (7; baseline), but ITI increased to 7-sec). Days 2-3 - 
Baseline (as above(7). Day 4 - Long ITI, Days 5-6 - Baseline. Day 7 - Long ITI
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TCA CCA ACG TAG CTG TCT TTC TG 
GCC ACA GGC CCC GCT GTT A 
ACC AGG GGC GAA GCC AAG CA
GGA GCC CGC CAT GCG TCT T
CGT CGC GTT CCC GCT CCA A 
Target genes
CTT GAG CGC AGG AAC CAG AG 
CGC GCA CTG AGA GAT GAC AG
CGA GCT GTC TTC CCA TCC A
Reference genes
AAC CCC GGT TAC CAG TGG CCT
TCT GGA GGA CTG TAA GAG GTA TGC 
AGA CGC ACA ATC TTG AGA GCA G
CTG GAG GCC AGC TCA AAC AT
ATC AAG AAG AGT AGT ACC GCT AGC ATT AC 
GCG GAA AAC CGG ATA AAA ACA CTC
AGT TTG TCC TCT GCG TGT GCA T 
TGT ACA TCC GCC GAT TAC CGC T
TCC GCA GTC GGA GGG CAG TA 
TTA CAA GAG GTT TGG GCG CT
ACA GAC CAG TAG ATC ATC ACT CC 
GGC TCC CAG GTC GAC ATT 
AGT GAT GAG TTC GCC CAA CC
CTT TGG GCC TCT TCC TGC AA
TCA GAG TCT TGA TGT AGT GAC GG 
ACC GTG TCA CAT TGT TCA TTC TC 
ACA GGT CTC TCC AGT GGG TTA
GGC TGC CTG ATG TTG TTC TT 
TGG TGG CAA CCA GAA GAC ACT T 
AGG TGA CAT TGT TTG AGA TGT CTT 
TGT CTT GGT AGT GTC AAG TTG T
TAT GTG GTC CTG ACC GTG CT 
CAC ATG TGT AGG CGC AGG AA
Primers
TCC ACA AAA TCA GGA AAA GCG T
CAG CCA ATG TAA ACC GGC AA
ATC GAG TTT CGC AGA GCC TT
TCC ACA GTG TCT GAA AGC CG
CCG TAT GTG ACA GGA CGC CA
TTT CCC ACC AGT CCC ATC ACA
CAG GAG TCA ACC TCC GCT TT 
TGA ATC TGA ACG CAC TGG CT 
TGA TCA CAT GAT GGG GAA TGA CG 
CAC CAC ACA CAC GAT CAC AAA G 
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Table	  3.	  mRNA	  expression	  for	  achesb55/+	  vs.	  ache+/+	  at	  9dpf	  and	  6	  months	  of	  age.	  All	  738	   expression	  ratios	  are	  reported	  relative	  to	  Bact,	  Rpl13a	  and	  eF1a.	  	  739	   	  740	  
	  741	  









adora2aa 9 4 5 0.9 1 0.45 '
chrna2 17 5 5 0.42 1 0.68 '
chrna3 17 5 5 0.42 1 0.68 '
chrna4 12 4 5 0.73 1 0.6 '
chrna5 18 5 5 0.31 1 0.72 '
chrna6 11 4 5 1 1 0.55 '
chrna7 14 4 5 0.41 1 0.7 '
chrnb2 9.5 4 5 0.9 1 0.475 '
chrnb3 8 4 5 0.73 1 0.4 '
chrnb4 10 4 5 1 1 0.5 '
drd1 9 4 5 0.9 1 0.45 '
drd2 11 4 5 1 1 0.55 '
drd3 10 5 5 0.69 1 0.4 '
htr1aa 12 4 5 0.73 1 0.6 '
optm1 13.5 4 5 0.41 1 0.675 '
slc6a2 14 4 5 0.41 1 0.7 '
slc6a3 14 5 5 0.85 1 0.56 '
slc6a4 16 5 5 0.55 1 0.64 '
adora2aa 51 8 8 0.05 0.9 0.797 '
chrna2 47 8 6 0.001 0.02 0.979 achesb55/+*/!
chrna3 33.5 8 8 0.9 1 0.523 '
chrna4 46 8 8 0.16 1 0.719 '
chrna5 94.5 8 8 0.003 0.05 1.477 achesb55/+*/!
chrna6 50 8 8 0.065 1 0.781 '
chrna7 50 8 8 0.065 1 0.781 '
chrnb2 52 8 8 0.038 0.68 0.813 '
chrnb3 28 8 8 0.72 1 0.438 '
chrnb4 50 8 8 0.065 1 0.781 '
drd1 54 8 8 0.02 0.36 0.844 '
drd2 53 8 7 0.002 0.036 0.946 achesb55/+*/!
drd3 57 8 8 0.007 0.126 0.891 '
htr1aa 54 8 8 0.02 0.36 0.844 '
optm1 53 8 8 0.03 0.54 0.828 '
slc6a2 55.5 8 8 0.01 0.18 0.867 '
slc6a3 45 8 7 0.054 0.972 0.804 '
slc6a4 25 8 6 1 1 0.521 '
Adult/(6/months)
/9/dpf
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